Literature DB >> 10779573

Identification of a 30 kDa antigen from leishmania (L.) chagasi amastigotes implicated in protective cellular reponses in a murine model.

A R Pinto1, C G Beyrodt, R A Lopes, C L Barbiéri.   

Abstract

An antigen of apparent molecular mass of 30 kDa, termed p30, was purified from Leishmania (L.) chagasi amastigotes after separation of parasite extracts by sodium dodecyl sulfate-polyacrylamide gel eletroctrophoresis followed by electroelution. The use of the purified antigen in lymphocyte cultures from BALB/c mice previously immunised with L. (L.) chagasi amastigotes led to high levels of proliferation. Animal immunisation with p30 plus complete Freund's adjuvant either by subcutaneous or intraperitoneal route led to comparable antigenic stimulation. Similar stimulation indices induced by p30 were also obtained when animals were immunised with Corynebacterium parvum as adjuvant by the intraperitoneal route. Detection of IL-2 and IFN-gamma in the supernatants from lymphocytes stimulated by p30 and inhibition of the production of these lymphokines in the presence of anti-CD4 strongly indicated the involvement of the Th1 subset in the responses elicited by p30 antigen. Immunisation of BALB/c mice with p30 provided partial protection against challenge with L. (L.) chagasi amastigotes, indicating a protective role for p30 and that Th1 can be related to accquired resistance to visceral leishmaniasis in a murine model. Further characterisation studies were performed by the use of a monoclonal antibody directed to a cysteine proteinase of 30 kDa from L. (L.) amazonensis amastigotes. Despite the cross-reactivity presented by p30 from both Leishmania species, the p30 from L. (L.) chagasi amastigotes lacks proteolytic activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10779573     DOI: 10.1016/s0020-7519(00)00037-0

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  6 in total

1.  Monoclonal antibody affinity purification of a 78 kDa membrane protein of Leishmania donovani of Indian origin and its role in host-parasite interaction.

Authors:  Mandira Mukherjee; Anindita Bhattacharyya; Swadesh Duttagupta
Journal:  J Biosci       Date:  2002-12       Impact factor: 1.826

2.  Ultrastructural and cytochemical identification of megasome in Leishmania (Leishmania) chagasi.

Authors:  Sanny O Alberio; Suzana S Dias; Flávio P Faria; Renato A Mortara; Clara L Barbiéri; Edna Freymüller Haapalainen
Journal:  Parasitol Res       Date:  2004-01-09       Impact factor: 2.289

3.  Treatment of Leishmania (Leishmania) Amazonensis-Infected Mice with a Combination of a Palladacycle Complex and Heat-Killed Propionibacterium acnes Triggers Protective Cellular Immune Responses.

Authors:  Carolina S Paladi; Danielle A M da Silva; Priscila D Motta; Daniel M Garcia; Daniela Teixeira; Ieda M Longo-Maugéri; Simone Katz; Clara L Barbiéri
Journal:  Front Microbiol       Date:  2017-03-06       Impact factor: 5.640

4.  Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis.

Authors:  Josie Haydée Lima Ferreira; Lucilene Dos Santos Silva; Ieda Maria Longo-Maugéri; Simone Katz; Clara Lúcia Barbiéri
Journal:  PLoS Negl Trop Dis       Date:  2014-03-13

5.  Comparison of the Effect of Two Purification Methods on the Immunogenicity of Recombinant Outer Membrane Protein H of Pasteurella multocida Serovar A:1.

Authors:  Arunee Thanasarasakulpong; Pichayanut Poolperm; Weerapongse Tangjitjaroen; Thanya Varinrak; Takuo Sawada; Dirk Pfeiffer; Nattawooti Sthitmatee
Journal:  Vet Med Int       Date:  2016-01-17

6.  Protective Cellular Immune Response Induction for Cutaneous Leishmaniasis by a New Immunochemotherapy Schedule.

Authors:  Danielle A M da Silva; Fabiana R Santana; Simone Katz; Daniel M Garcia; Daniela Teixeira; Ieda M Longo-Maugéri; Clara L Barbiéri
Journal:  Front Immunol       Date:  2020-03-03       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.